HRP20191092T1 - Pripravci za oralno doziranje s odgođenim otpuštanjem koji sadrže amorfni cddo-me - Google Patents
Pripravci za oralno doziranje s odgođenim otpuštanjem koji sadrže amorfni cddo-me Download PDFInfo
- Publication number
- HRP20191092T1 HRP20191092T1 HRP20191092T HRP20191092T1 HR P20191092 T1 HRP20191092 T1 HR P20191092T1 HR P20191092 T HRP20191092 T HR P20191092T HR P20191092 T1 HRP20191092 T1 HR P20191092T1
- Authority
- HR
- Croatia
- Prior art keywords
- dosage form
- solid dosage
- form according
- hydrophilic binder
- proportion
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 9
- 230000003111 delayed effect Effects 0.000 title 1
- 239000007909 solid dosage form Substances 0.000 claims 14
- 239000011230 binding agent Substances 0.000 claims 10
- 238000009472 formulation Methods 0.000 claims 6
- WPTTVJLTNAWYAO-KPOXMGGZSA-N Bardoxolone methyl Chemical group C([C@@]12C)=C(C#N)C(=O)C(C)(C)[C@@H]1CC[C@]1(C)C2=CC(=O)[C@@H]2[C@@H]3CC(C)(C)CC[C@]3(C(=O)OC)CC[C@]21C WPTTVJLTNAWYAO-KPOXMGGZSA-N 0.000 claims 4
- 239000002245 particle Substances 0.000 claims 4
- 239000001913 cellulose Substances 0.000 claims 3
- 229920002678 cellulose Polymers 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims 2
- RFIMISVNSAUMBU-UHFFFAOYSA-N 2-(hydroxymethyl)-2-(prop-2-enoxymethyl)propane-1,3-diol Chemical compound OCC(CO)(CO)COCC=C RFIMISVNSAUMBU-UHFFFAOYSA-N 0.000 claims 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 2
- 108010010803 Gelatin Proteins 0.000 claims 2
- 229920000881 Modified starch Polymers 0.000 claims 2
- 229920002472 Starch Polymers 0.000 claims 2
- 229940086737 allyl sucrose Drugs 0.000 claims 2
- 229920006318 anionic polymer Polymers 0.000 claims 2
- 229920000159 gelatin Polymers 0.000 claims 2
- 235000019322 gelatine Nutrition 0.000 claims 2
- 235000011852 gelatine desserts Nutrition 0.000 claims 2
- 229920001519 homopolymer Polymers 0.000 claims 2
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims 2
- 229940117841 methacrylic acid copolymer Drugs 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 229920001282 polysaccharide Polymers 0.000 claims 2
- 238000001694 spray drying Methods 0.000 claims 2
- 235000019698 starch Nutrition 0.000 claims 2
- 239000008107 starch Substances 0.000 claims 2
- 229920001661 Chitosan Polymers 0.000 claims 1
- 239000001856 Ethyl cellulose Substances 0.000 claims 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- 229920002301 cellulose acetate Polymers 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 229920001249 ethyl cellulose Polymers 0.000 claims 1
- 235000019325 ethyl cellulose Nutrition 0.000 claims 1
- 239000008273 gelatin Substances 0.000 claims 1
- 230000009477 glass transition Effects 0.000 claims 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 claims 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 229920000609 methyl cellulose Polymers 0.000 claims 1
- 239000001923 methylcellulose Substances 0.000 claims 1
- -1 propylcellulose Polymers 0.000 claims 1
- 239000007962 solid dispersion Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
Claims (14)
1. Čvrsti oblik doziranja koji sadrži
(A) čestice koje se sastoje od amorfnog bardoksolon metila i staklaste pomoćne tvari, gdje je oblik doziranja naznačen time što ima jednu temperaturu staklenja, u smjesi s
(B) česticama najmanje jednog hidrofilnog veziva, kojeg se bira iz skupine koju čine:
(1) prirodni ugljikohidratni polimeri, koje se bira između škroba i predželatiniranog škroba;
(2) želatina ili modificirane želatine;
(3) hitozan;
(4) anionski polimeri, koje se bira između homopolimera akrilne kiseline umreženih s alilsaharozom ili alilpentaeritritolom, i
(5) pomoćne tvari na bazi celuloze, koje se bira iz skupine koju čine C3-C10 alkilhidroksimetilceluloza, arilhidroksimetilceluloza, te supstituirana arilhidroksimetilceluloza.
2. Čvrsti oblik doziranja u skladu s patentnim zahtjevom 1, naznačen time što je hidrofilno vezivo pomoćna tvar na bazi celuloze.
3. Čvrsti oblik doziranja u skladu s patentnim zahtjevom 1, naznačen time što navedene čestice (A) su čvrsta disperzija amorfnog bardoksolon metila u staklastom matriksu.
4. Čvrsti oblik doziranja u skladu s patentnim zahtjevom 1, naznačen time što su navedene čestice (A) rezultat postupka koji se sastoji u sušenju raspršivanjem smjese bardoksolon metila s kopolimerom metakrilne kiseline.
5. Čvrsti oblik doziranja u skladu s patentnim zahtjevom 4, naznačen time što se navedeni postupak sastoji u sušenju raspršivanjem 4:6 smjese bardoksolon metila s kopolimerom metakrilne kiseline.
6. Čvrsti oblik doziranja u skladu s patentnim zahtjevom 1, naznačen time što je pomoćna tvar na bazi celuloze C3-C10 alkilhidroksimetilceluloza, koju se bira iz skupine koju čine metilceluloza, etilceluloza, propilceluloza, hidroksimetilceluloza, hidroksipropilceluloza, te celulozni acetat.
7. Čvrsti oblik doziranja u skladu s patentnim zahtjevom 1, naznačen time što je hidrofilno vezivo prirodni ugljikohidratni polimer, kojeg se bira između škroba i predželatiniranog škroba.
8. Čvrsti oblik doziranja u skladu s patentnim zahtjevom 1, naznačen time što je hidrofilno vezivo anionski polimer, kojeg se bira između homopolimera akrilne kiseline umreženih s alilsaharozom ili alilpentaeritritolom.
9. Čvrsti oblik doziranja u skladu s patentnim zahtjevom 1, naznačen time što je udio hidrofilnog veziva između 1% i 40% (tež./tež.) od ukupne formulacije.
10. Čvrsti oblik doziranja u skladu s patentnim zahtjevom 9, naznačen time što je udio hidrofilnog veziva između 2% i 20% (tež./tež.) od ukupne formulacije.
11. Čvrsti oblik doziranja u skladu s patentnim zahtjevom 9, naznačen time što je udio hidrofilnog veziva između 4% i 10% (tež./tež.) od ukupne formulacije.
12. Čvrsti oblik doziranja u skladu s patentnim zahtjevom 9, naznačen time što je udio hidrofilnog veziva između 5% i 7,5% (tež./tež.) od ukupne formulacije.
13. Čvrsti oblik doziranja u skladu s patentnim zahtjevom 9, naznačen time što je udio hidrofilnog veziva između 7% i 7,5% (tež./tež.) od ukupne formulacije.
14. Čvrsti oblik doziranja u skladu s patentnim zahtjevom 9, naznačen time što je udio hidrofilnog veziva 7% (tež./tež.) od ukupne formulacije.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15260809P | 2009-02-13 | 2009-02-13 | |
| EP17181174.8A EP3254675B1 (en) | 2009-02-13 | 2010-02-12 | Delayed release, oral dosage compositions that contain amorphous cddo-me |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20191092T1 true HRP20191092T1 (hr) | 2019-11-29 |
Family
ID=42335073
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20171639TT HRP20171639T1 (hr) | 2009-02-13 | 2017-10-26 | ORALNI PRIPRAVCI DOZIRANJA S ODGOĐENIM OSLOBAĐANJEM KOJI SADRŽE AMORFNI CDDO-Me |
| HRP20191092 HRP20191092T1 (hr) | 2009-02-13 | 2019-06-17 | Pripravci za oralno doziranje s odgođenim otpuštanjem koji sadrže amorfni cddo-me |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20171639TT HRP20171639T1 (hr) | 2009-02-13 | 2017-10-26 | ORALNI PRIPRAVCI DOZIRANJA S ODGOĐENIM OSLOBAĐANJEM KOJI SADRŽE AMORFNI CDDO-Me |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US8747901B2 (hr) |
| EP (2) | EP2395979B1 (hr) |
| JP (1) | JP5775464B2 (hr) |
| KR (2) | KR101483203B1 (hr) |
| CN (2) | CN102387789A (hr) |
| AU (1) | AU2010213594B2 (hr) |
| BR (1) | BRPI1008023B8 (hr) |
| CA (1) | CA2752048C (hr) |
| CO (1) | CO6361904A2 (hr) |
| CY (2) | CY1119595T1 (hr) |
| DK (2) | DK2395979T3 (hr) |
| EA (1) | EA023652B1 (hr) |
| ES (2) | ES2731601T3 (hr) |
| HK (1) | HK1220130A1 (hr) |
| HR (2) | HRP20171639T1 (hr) |
| HU (2) | HUE044005T2 (hr) |
| IL (1) | IL214258A (hr) |
| LT (2) | LT3254675T (hr) |
| MX (1) | MX2011008344A (hr) |
| MY (1) | MY173715A (hr) |
| NO (1) | NO2395979T3 (hr) |
| NZ (1) | NZ594488A (hr) |
| PL (2) | PL2395979T3 (hr) |
| PT (2) | PT2395979T (hr) |
| SG (1) | SG173601A1 (hr) |
| SI (2) | SI2395979T1 (hr) |
| TR (1) | TR201909743T4 (hr) |
| WO (1) | WO2010093944A2 (hr) |
| ZA (1) | ZA201105630B (hr) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6326507B1 (en) | 1998-06-19 | 2001-12-04 | Trustees Of Dartmouth College | Therapeutic compounds and methods of use |
| AU2009203941B2 (en) | 2008-01-11 | 2015-03-12 | Reata Pharmaceuticals Holdings, LLC | Synthetic triterpenoids and methods of use in the treatment of disease |
| BRPI0911422B8 (pt) | 2008-04-18 | 2021-05-25 | Reata Pharmaceuticals Inc | compostos moduladores inflamatórios antioxidantes, composição farmacêutica e usos dos mesmos |
| WO2009146218A2 (en) | 2008-04-18 | 2009-12-03 | Reata Pharmaceuticals, Inc. | Compounds including an anti-inflammatory pharmacore and methods of use |
| SI2276493T1 (sl) | 2008-04-18 | 2019-04-30 | Reata Pharmaceuticals, Inc. | Antioksidantni modulatorji vnetja: derivati oleanolne kisline z amino in drugimi modifikacijami pri C-17 |
| TWI442925B (zh) | 2008-04-18 | 2014-07-01 | Reata Pharmaceuticals Inc | 抗氧化性發炎調節劑：ｃ－環飽和之齊墩果酸衍生物 |
| WO2010011782A1 (en) | 2008-07-22 | 2010-01-28 | Trustees Of Dartmouth College | Monocyclic cyanoenones and methods of use thereof |
| AU2010213594B2 (en) | 2009-02-13 | 2013-11-14 | Reata Pharmaceuticals Holdings, LLC | Delayed release, oral dosage compositions that contain amorphous CDDO-Me |
| SI2558105T1 (sl) | 2010-04-12 | 2020-02-28 | Reata Pharmaceuticals, Inc. | Bardoksolon metil za zdravljenje debelosti |
| ME02973B (me) | 2010-12-17 | 2018-07-20 | Reata Pharmaceuticals Inc | Pirazolil i pirimidinil triciklični enoni kao antioksidantni modulatori inflamacije |
| EA026847B1 (ru) | 2011-03-11 | 2017-05-31 | Рита Фармасьютикалз, Инк. | C4-монометилтритерпеноидные производные и способы их применения |
| CN103156861B (zh) * | 2011-12-08 | 2015-11-25 | 陈丽梅 | 齐敦果酸衍生物及其可药用盐在治疗糖尿病眼病中的应用 |
| US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
| US9504679B2 (en) | 2011-12-19 | 2016-11-29 | Bjoern Colin Kahrs | Pharmaceutical compositions comprising glitazones and Nrf2 activators |
| HUE053113T2 (hu) | 2012-04-27 | 2021-06-28 | Reata Pharmaceuticals Inc | Bardoxolon-metil 2,2-difluorpropionamid-származéka, annak gyógyszerkészítményei és polimorfjai bizonyos betegségek kezelésében történõ alkalmazásra |
| US8981144B2 (en) | 2012-05-08 | 2015-03-17 | Trustees Of Dartmouth College | Method for synthesizing 2-cyano-3,12-dioxoolean-1, 9(11)-dien-28-oic acid methyl ester and derivatives thereof |
| US8921419B2 (en) | 2012-05-08 | 2014-12-30 | Trustees Of Dartmouth College | Triterpenoids and compositions containing the same |
| WO2013188818A1 (en) | 2012-06-15 | 2013-12-19 | Reata Pharmaceuticals, Inc. | A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof |
| WO2014040073A1 (en) | 2012-09-10 | 2014-03-13 | Reata Pharmaceuticals, Inc. | C13-hydroxy derivatives of oleanolic acid and methods of use thereof |
| ES2731758T3 (es) | 2012-09-10 | 2019-11-18 | Reata Pharmaceuticals Inc | Derivados de alcanodiil y alquenodiil de c17 del ácido oleanólico y métodos de uso de los mismos |
| US9512094B2 (en) | 2012-09-10 | 2016-12-06 | Reata Pharmaceuticals, Inc. | C17-heteroaryl derivatives of oleanolic acid and methods of use thereof |
| AR096046A1 (es) | 2013-04-24 | 2015-12-02 | Abbvie Inc | Derivados de 2,2-difluoropropanamida de metil bardoxolona, formas polimórficas y métodos de uso |
| BR112016003454B1 (pt) | 2013-08-23 | 2023-02-14 | Reata Pharmaceuticals, Inc. | Uso de composto de metil bardoxolona |
| US20170333450A1 (en) | 2014-10-31 | 2017-11-23 | The Regents Of The University Of California | Compositions and methods for treating hiv-associated cognitive dysfunction |
| WO2016130927A1 (en) | 2015-02-12 | 2016-08-18 | Reata Pharmaceuticals, Inc. | Imidazolyl tricyclic enones as antioxidant iflammation modulators |
| CN108290922B (zh) | 2015-09-23 | 2021-12-07 | 里亚塔医药公司 | 用于抑制il-17和其它用途的c4-改性的齐墩果酸衍生物 |
| WO2018089539A1 (en) | 2016-11-08 | 2018-05-17 | Reata Pharmaceuticals, Inc. | Methods of treating alport syndrome using bardoxolone methyl or analogs thereof |
| PE20191490A1 (es) | 2016-12-16 | 2019-10-21 | Reata Pharmaceuticals Inc | DERIVADOS DE LA PIRIMIDIN ENONA TRICICLICA PARA LA INHIBICION DE RORy Y OTROS USOS |
| WO2019014412A1 (en) | 2017-07-13 | 2019-01-17 | Pliva Hrvatska D.O.O. | NOVEL CRYSTALLINE POLYMORPHIC FORMS OF METHYL BARDOXOLONE |
| US11708463B2 (en) | 2018-04-06 | 2023-07-25 | Capsugel Belgium Nv | Spray drying process for low aspect ratio particles comprising poly[(methyl methacrylate)-co-(methacrylic acid)] |
| TW202038918A (zh) | 2018-11-27 | 2020-11-01 | 日商協和麒麟股份有限公司 | 醫藥組合物 |
| KR20230022164A (ko) | 2020-05-09 | 2023-02-14 | 리아타 파마슈티컬즈 홀딩스, 엘엘씨 | 바독솔론 메틸 또는 이의 유사체를 사용하여 covid-19를 치료하는 방법 |
| WO2022126129A1 (en) | 2020-12-11 | 2022-06-16 | Reata Pharmaceuticals, Inc. | Synthetic triterpenoids for use in therapy |
| CN114558019A (zh) * | 2022-03-26 | 2022-05-31 | 中国科学院昆明动物研究所 | 一种Rab13基因抑制剂及应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6326507B1 (en) | 1998-06-19 | 2001-12-04 | Trustees Of Dartmouth College | Therapeutic compounds and methods of use |
| US7435755B2 (en) * | 2000-11-28 | 2008-10-14 | The Trustees Of Dartmouth College | CDDO-compounds and combination therapies thereof |
| JP2008110962A (ja) * | 2006-08-02 | 2008-05-15 | Santen Pharmaceut Co Ltd | Ｎｒｆ２活性化物質を有効成分として含む角結膜障害の予防または治療剤 |
| JP4315182B2 (ja) * | 2006-10-30 | 2009-08-19 | ミツミ電機株式会社 | カメラモジュール |
| JP2008247898A (ja) | 2007-03-08 | 2008-10-16 | Santen Pharmaceut Co Ltd | トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤 |
| US8088824B2 (en) | 2007-08-15 | 2012-01-03 | Reata Pharmaceuticals Inc. | Forms of CDDO methyl ester |
| AU2009203941B2 (en) | 2008-01-11 | 2015-03-12 | Reata Pharmaceuticals Holdings, LLC | Synthetic triterpenoids and methods of use in the treatment of disease |
| AU2010213594B2 (en) * | 2009-02-13 | 2013-11-14 | Reata Pharmaceuticals Holdings, LLC | Delayed release, oral dosage compositions that contain amorphous CDDO-Me |
-
2010
- 2010-02-12 AU AU2010213594A patent/AU2010213594B2/en active Active
- 2010-02-12 PL PL10704298T patent/PL2395979T3/pl unknown
- 2010-02-12 EP EP10704298.8A patent/EP2395979B1/en active Active
- 2010-02-12 LT LTEP17181174.8T patent/LT3254675T/lt unknown
- 2010-02-12 KR KR1020117021250A patent/KR101483203B1/ko active IP Right Grant
- 2010-02-12 MY MYPI2011003694A patent/MY173715A/en unknown
- 2010-02-12 LT LTEP10704298.8T patent/LT2395979T/lt unknown
- 2010-02-12 PT PT107042988T patent/PT2395979T/pt unknown
- 2010-02-12 EA EA201190092A patent/EA023652B1/ru not_active IP Right Cessation
- 2010-02-12 JP JP2011550279A patent/JP5775464B2/ja active Active
- 2010-02-12 SI SI201031570T patent/SI2395979T1/sl unknown
- 2010-02-12 MX MX2011008344A patent/MX2011008344A/es active IP Right Grant
- 2010-02-12 WO PCT/US2010/024127 patent/WO2010093944A2/en active Application Filing
- 2010-02-12 NZ NZ594488A patent/NZ594488A/xx unknown
- 2010-02-12 PL PL17181174T patent/PL3254675T3/pl unknown
- 2010-02-12 US US13/201,398 patent/US8747901B2/en active Active
- 2010-02-12 KR KR1020147001850A patent/KR20140016441A/ko not_active Application Discontinuation
- 2010-02-12 TR TR2019/09743T patent/TR201909743T4/tr unknown
- 2010-02-12 DK DK10704298.8T patent/DK2395979T3/da active
- 2010-02-12 BR BRPI1008023A patent/BRPI1008023B8/pt active IP Right Grant
- 2010-02-12 CA CA2752048A patent/CA2752048C/en active Active
- 2010-02-12 SG SG2011057122A patent/SG173601A1/en unknown
- 2010-02-12 SI SI201031906T patent/SI3254675T1/sl unknown
- 2010-02-12 CN CN201080007105XA patent/CN102387789A/zh active Pending
- 2010-02-12 EP EP17181174.8A patent/EP3254675B1/en active Active
- 2010-02-12 ES ES17181174T patent/ES2731601T3/es active Active
- 2010-02-12 NO NO10704298A patent/NO2395979T3/no unknown
- 2010-02-12 DK DK17181174.8T patent/DK3254675T3/da active
- 2010-02-12 HU HUE17181174A patent/HUE044005T2/hu unknown
- 2010-02-12 PT PT17181174T patent/PT3254675T/pt unknown
- 2010-02-12 CN CN201510540397.8A patent/CN105232471A/zh active Pending
- 2010-02-12 ES ES10704298.8T patent/ES2646816T3/es active Active
- 2010-02-12 HU HUE10704298A patent/HUE035013T2/en unknown
-
2011
- 2011-07-24 IL IL214258A patent/IL214258A/en active IP Right Grant
- 2011-07-29 ZA ZA2011/05630A patent/ZA201105630B/en unknown
- 2011-08-09 CO CO11100847A patent/CO6361904A2/es not_active Application Discontinuation
-
2014
- 2014-04-30 US US14/266,031 patent/US9155721B2/en active Active
-
2016
- 2016-07-13 HK HK16108241.2A patent/HK1220130A1/zh unknown
-
2017
- 2017-10-26 HR HRP20171639TT patent/HRP20171639T1/hr unknown
- 2017-11-13 CY CY20171101183T patent/CY1119595T1/el unknown
-
2019
- 2019-06-17 HR HRP20191092 patent/HRP20191092T1/hr unknown
- 2019-07-17 CY CY20191100761T patent/CY1122066T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191092T1 (hr) | Pripravci za oralno doziranje s odgođenim otpuštanjem koji sadrže amorfni cddo-me | |
| PE20211976A1 (es) | Composiciones de liberacion retardada de linaclotida | |
| HRP20200297T1 (hr) | Dozni oblici apiksabana | |
| RU2014101227A (ru) | Композиция покрытия, подходящая для фармацевтических или нутрицевтических лекарственных форм | |
| WO2012091153A3 (en) | Orally disintegrating tablet | |
| JP2019147832A5 (hr) | ||
| JP2011510104A5 (hr) | ||
| HRP20171578T1 (hr) | Čvrsta disperzija | |
| JP2011241218A5 (hr) | ||
| BR112015021403A2 (pt) | cápsulas e comprimidos sólidos de benzonatato de liberação modificada | |
| RU2016151163A (ru) | Композиции, включающие электрогидродинамически полученные волокна, для нанесения заданных доз активного вещества на кожу или слизистую оболочку | |
| HRP20150123T1 (hr) | Plutajući farmaceutski oblici kontroliranog oslobađanja | |
| HRP20161429T1 (hr) | Farmaceutski sastav | |
| BRPI0513921A (pt) | composição para cuidado oral, e, método para liberar um ativo para cuidado oral | |
| RU2015110824A (ru) | Фармацевтическая или нутрицевтическая композиция с замедленным высвобождением и стойкостью к воздействию этанола | |
| JP2015120756A5 (hr) | ||
| BR112012020514A2 (pt) | processo para produzir um nanocompósito hidrofóbico de celulose nanocristalina e um monômero de vinila polimerizado hidrofóbico, nanocompósito hidrofóbico de celulose nanocristalina e monômero de vinila polimerizado hidrofóbico, e composição. | |
| JP2006274272A5 (hr) | ||
| CA2797812A1 (en) | Enteric tablet | |
| JP2014520171A5 (hr) | ||
| RU2005122439A (ru) | Композиция, включающая фенофибриновую кислоту, ее физиологически приемлемую соль или производное | |
| ES2572277T3 (es) | Composiciones fijadoras para el cabello | |
| AR071970A1 (es) | Composicion de liberacion pulsatil de sildenafil y proceso para prepararla | |
| RU2008136098A (ru) | Таблетки, покрытые оболочкой, способ их изготовления и сопутствующие применения | |
| RU2012131952A (ru) | Фармацевтическая композиция с модифицированным высвобождением, содержащая реин или диацереин и способ ее получения |